Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
First half 2021 results presentation
Operating income, growth figures, profitability and how our products have behaved.
Wed, 28/07/2021 - 00:00
0 min
Español
IMG_7355baja(1).jpg
Download related document
Select rating
Give First half 2021 results presentation 1/5
Give First half 2021 results presentation 2/5
Give First half 2021 results presentation 3/5
Give First half 2021 results presentation 4/5
Give First half 2021 results presentation 5/5
No votes yet
Related
ROVI achieves an increase of 29% in operating income and 74% in EBITDA
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research...
6 min
13/05/2021
First quarter 2021 results presentation
0 min
13/05/2021
ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna
Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research,...
2 min
29/04/2021
See More
Email
Facebook
Twitter
LinkedIn
IMG_7355baja(1).jpg